Skip to main content
SpringerLink
Log in

Clinical reversal of multidrug resistance

  • Chapter
Anticancer Drug Resistance

Part of the book series: Cancer Treatment and Research ((CTAR,volume 73))

Abstract

The multidrug transporter, P-glycoprotein, is expressed in many human cancers and normal tissues [1–9]. Various aspects of the nature of mdr genes that encode P-glycoprotein and confer ‘classical’ multidrug resistance (MDR) are described in previous chapters in this volume. This chapter will focus on clinical implications of MDR and approaches to its reversal or modulation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pastan, I. and Gottesman, M.M. 1987. Multidrug resistance in human cancer. N. Engl. J. Med. 316: 1388–1393.

    Article  PubMed  CAS  Google Scholar 

  2. Roninson, I.B. (ed). 1991. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press: New York and London.

    Google Scholar 

  3. Nooter, K. and Herwijer, H. 1991. Multidrug resistance (MDR) in human cancers. Br. J. Cancer 63: 663–669.

    Article  PubMed  CAS  Google Scholar 

  4. Goldstein, L.J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G.M., Lieber, M., Cossman, J., Gottesman, M.M., and Pastan, I. 1989. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81: 116–124.

    Article  PubMed  CAS  Google Scholar 

  5. Fojo, A., Ueda, K., Slamon, DJ., Poplack, D.C., Gottesman, M.M., and Pastan, I. 1987. Expression of a multidrug-resistant gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 84: 265–269.

    Article  PubMed  CAS  Google Scholar 

  6. Thiebaut, F., Tsuruo,T., Hamada, H., Gottesman, M.M., Pastan, I., and Willingham, M.C. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84: 7735–7738.

    Article  PubMed  CAS  Google Scholar 

  7. Cordon-Cardo, C., O’Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R., and Bertino, J.R. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86: 695–698.

    Article  PubMed  CAS  Google Scholar 

  8. Chaudhary, P.M. and Roninson, I.B. 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85–92.

    Article  PubMed  CAS  Google Scholar 

  9. Marie, J.P., Brophy, N.B., Ehsan, M.N., Aihara, Y., Mohamed, N.A., Cornbleet, J., Chao, N.J., and Sikic, B.I. 1992. Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br. J. Haematol. 81: 145–152.

    Article  PubMed  CAS  Google Scholar 

  10. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41: 1967–1972.

    PubMed  CAS  Google Scholar 

  11. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. 1982. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42: 4730–4733.

    PubMed  CAS  Google Scholar 

  12. Ford, J.M. and Hait, W.N. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev 42: 155–199.

    PubMed  CAS  Google Scholar 

  13. Ganapathi, R. and Grabowski, D. 1983. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 43: 3696–3699.

    PubMed  CAS  Google Scholar 

  14. Slater, L., Sweet, P., Stupecky, M., and Gupta, S. 1986. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 77: 1405–1408.

    Article  PubMed  CAS  Google Scholar 

  15. Willingham, M., Cornwell, M., Cardarelli, C., Gottesman, M.M., and Pastan, I. 1986. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and sensitive KB cells: effects of verapamil and other drugs. Cancer Res. 46: 5941–5946.

    PubMed  CAS  Google Scholar 

  16. Cornwell, M., Pastan, I., and Gottesman, M. 1987. Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262: 2166–2170.

    PubMed  CAS  Google Scholar 

  17. Naito, M. and Tsuruo, T. 1989. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res. 49: 1452–1455.

    PubMed  CAS  Google Scholar 

  18. Akiyama, S.-I., Cornwell, M.M., Kuwano, M., Pastan, I., and Gottesman, M.M. 1987. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol. Pharmacol. 33: 144–147.

    Google Scholar 

  19. Chan, H.S., Thorner, P.S., Haddad, G., and Ling, V. 1990. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 8: 689–704.

    PubMed  CAS  Google Scholar 

  20. Chan, H.S., Haddad, G., Thorner, P.S., De Boer, G., Lin, Y.P., Ondrusek, N., Yeger, H., and Ling, V. 1991. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 325: 1608–1614.

    Article  PubMed  CAS  Google Scholar 

  21. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O.A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent P., and Havelec, L. 1991. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 83: 708–712.

    Article  PubMed  CAS  Google Scholar 

  22. Marie, J.P., Zittoun, R., and Sikic, B.I. 1991. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586–592.

    PubMed  CAS  Google Scholar 

  23. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., and Fiere, D. 1992. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphocytic leukemia cells at diagnosis. Blood 79: 473–476.

    PubMed  CAS  Google Scholar 

  24. Holzmayer, T.A., Hilsenbeck, S., Von Hoff, D.D., and Roninson, I.B. 1992. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J. Natl. Cancer Inst. 84: 1486–1491.

    Article  PubMed  CAS  Google Scholar 

  25. Chabner, B.A. and Wilson, W. 1991. Reversal of multidrug resistance. J. Natl. Cancer Inst. 9: 4–6.

    CAS  Google Scholar 

  26. Twentyman, P.R. 1992. MDR1 (P-glycoprotein) gene expression-implications for resistance modifier trials. J. Natl. Cancer Inst. 84: 1458–1460.

    Article  PubMed  CAS  Google Scholar 

  27. Bissett, D., Kerr, D.J., Cassidy, J., Meredith, P., Trangott, U., and Kaye, S.B. 1991. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br. J. Cancer 64: 1168–1171.

    Article  PubMed  CAS  Google Scholar 

  28. Cairo, M.S., Siegel, S., Anas, N., and Sender, L. 1989. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatrie tumors. Cancer Res. 49: 1063–1066.

    PubMed  CAS  Google Scholar 

  29. Dalmark, M., Pals, H., and Johnsen, A.H. 1991. Doxorubicin in combination with verapamil in advanced colorectal cancer: A phase II trial. Acta Oncol. 30: 23–26.

    Article  PubMed  CAS  Google Scholar 

  30. Dalton, W.S., Grogan, T.M., Meltzer, P.S., Scheper, R.J., Durie, B.G.M., Taylor, C.W., Miller, T.P., and Salmon, S.E. 1989. Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7: 415–424.

    PubMed  CAS  Google Scholar 

  31. Hendrick, A.M., Harris, A.L., and Cantwell, B.M.J. 1991. Verapamil with mitoxantrone for advanced ovarian cancer: a negative phase II trial. Ann. Oncol. 2: 71–72.

    PubMed  CAS  Google Scholar 

  32. Kerr, DJ., Graham, J., Cummings, J., Morrison, J.G., Thompson, G.G., Brodie, M.J., and Kaye, S.B. 1986. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18: 239–242.

    Article  PubMed  CAS  Google Scholar 

  33. Miller, T.P., Grogan, T.M., Dalton, W.S., Spier, C.M., Scheper, R.J., and Salmon, S.E. 1991. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9: 17–24.

    PubMed  CAS  Google Scholar 

  34. Ohi, Y., Shirahama, T., Kawahara, M., Matsumura, Y., Tsushima, T., and Ohashi, Y. 1992. Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. Cancer Chemother. Pharmacol. 30: S50–S54.

    Article  PubMed  Google Scholar 

  35. Ozols, R.F., Cunnion, R.E., Klecker, R.W., Hamilton, T.C., Ostchega, Y., Parrillo, J.E., and Young, R.C. 1987. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5: 641–647.

    PubMed  CAS  Google Scholar 

  36. Presant, C.A., Kennedy, P.S., Wiseman, C., Gala, K., Bouzaglou, A., Wyres, M., and Naessig, V. 1986. Verapamil reversal of clinical doxorubicin resistance in human cancer. Am. J. Clin. Oncol. 9: 355–357.

    Article  CAS  Google Scholar 

  37. Salmon, S.E., Dalton, W.S., Grogan, R.M., Plezia, P., Lehnert, M., Roe, D.J., and Miller, T.P. 1991. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78: 44–50.

    PubMed  CAS  Google Scholar 

  38. Bertrand, Y., Capdeville, R., Balduck, N., and Philippe, N. 1992. Cyclosporin A used to reverse drug resistance increases vincristine neurotoxicity. Am. J. Hematol. 40: 158–159.

    Article  PubMed  CAS  Google Scholar 

  39. Klike, O. and Osieka, R. 1985. Interaction of cyclosporin A with antineoplastic agents. Klin. Wochenschr. 63: 1081–1082.

    Article  Google Scholar 

  40. Lum, B.L., Kaubisch, S., Yahanda, A.M., Adler, K.M., Jew, L., Ehsan, M.N., Brophy, N.A., Halsey, J., Gosland, M.P., and Sikic, B.I. 1992. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10: 1635–1642.

    PubMed  CAS  Google Scholar 

  41. Rodenburg, C.J., Nooter, K., Herweijer, H., Seynaeve, C., Oosterom, R., Stoter, G., and Verweij, J. 1991. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann. Oncol. 2: 305–306.

    PubMed  CAS  Google Scholar 

  42. Sonneveld, P., Durie, B.G.M., Lokhorst, H.M., Marie J.-P., Solbu, G., Suciu, S., Zittoun, R., Löwenberg, B., and Nooter, K. 1992. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255–259.

    Article  PubMed  CAS  Google Scholar 

  43. Sonneveld, P. and Nooter, K. 1990. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br. J. Haematol. 75: 208–211.

    Article  PubMed  CAS  Google Scholar 

  44. Verweij, J., Herweijer, H., Oosterom, R., van der Burg, M.E.L., Planting, A.S.T., Seynaeve, C., Stoter, G., and Nooter, K. 1991. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br. J. Cancer. 64: 361–364.

    Article  PubMed  CAS  Google Scholar 

  45. Yahanda, A.M., Adler, K.M., Fisher, G.A., Brophy, N.A., Halsey, J., Hardy, R.J., Gosland, M.P., Lum, B.L., and Sikic, B.I. 1992. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol. 10: 1624–1634.

    PubMed  CAS  Google Scholar 

  46. Figueredo, A., Arnold, A., Goodyear, M., Findlay, B., Neville, A., Normandeau, R., and Jones, A. 1990. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer: a phase I/II study. Cancer 65: 1895–1902.

    Article  PubMed  CAS  Google Scholar 

  47. Jones, R.D., Kerr, DJ., Harnett, A.N., Rankin, E.M., Ray, S., and Kaye, S.B. 1990. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br. J. Cancer 62: 133–135.

    Article  PubMed  CAS  Google Scholar 

  48. Miller, R.L., Bukowski, R.M., Budd, G.T., Purvis, J., Weick, J.K., Shepard, K., Midha, K.K., and Ganapathi, R. 1988. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J. Clin. Oncol. 6: 880–888.

    PubMed  CAS  Google Scholar 

  49. Millward, M.J., Cantwell, B.M.J., Lien, E.A., Carmichael, J., and Harris, A.L. 1992. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur. J. Cancer 28A: 805–810.

    Article  PubMed  CAS  Google Scholar 

  50. Philip, P.A., Joel, S., Monkman, S.C., Dolega-Ossowski, E., Tonkin, K., Carmichael, J., Idle, J.R., and Harris, A.L. 1992. A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. Br. J. Cancer 65: 267–270.

    Article  PubMed  CAS  Google Scholar 

  51. Solary, E., Caillot, D., Chauffert, B., Casanovas, R.O., Dumas, M., Maynadie, M., and Guy, H. 1992. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemias. J. Clin. Oncol. 10: 1730–1736.

    PubMed  CAS  Google Scholar 

  52. Stuart, N.S.A., Philip, P., Harris, A.L., Tonkin, K., Houlbrook, S., Kirk, J., Lien, E.A., and Carmichael, J. 1992. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br. J. Cancer 66: 833–839.

    Article  PubMed  CAS  Google Scholar 

  53. Trump, D.L., Smith, D.C., Ellis, P.G., Rogers, M.P., Schold, S.C., Winer, E.P., Panella, T.J., Jordan, V.C., and Fine, R.L. 1992. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J. Natl. Cancer Inst. 84: 1811–1816.

    Article  PubMed  CAS  Google Scholar 

  54. Horton, J.K., Thimmaiah K.N., Houghton, J.A., Horowitz, M.E., and Houghton, P.J. 1989. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem. Pharmacol. 38: 1727–1736.

    Article  PubMed  CAS  Google Scholar 

  55. Lehnert, M. 1993. Reversal of P-glycoprotein-associated multidrug resistance: the challenge continues. Eur. J. Cancer 29A: 636–638.

    Article  PubMed  CAS  Google Scholar 

  56. Boesch, D., Gaveriaux, X., Jachez, B., et al. 1991. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC833. Cancer Res. 51: 4226–4233.

    PubMed  CAS  Google Scholar 

  57. Twentyman, P.R. and Bleehen, N.M. 1991. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur. J. Cancer 27: 1639–1642.

    Article  PubMed  CAS  Google Scholar 

  58. Hamada, H. and Tsuruo, T. 1986. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 83: 7785–7789.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Branimir I. Sikic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George A. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bert L. Lum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nathalie A. Brophy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne M. Yahanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kent M. Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joanne Halsey
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Lori J. Goldstein  & Robert F. Ozols  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sikic, B.I. et al. (1994). Clinical reversal of multidrug resistance. In: Goldstein, L.J., Ozols, R.F. (eds) Anticancer Drug Resistance. Cancer Treatment and Research, vol 73. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2632-2_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2632-2_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6129-9

  • Online ISBN: 978-1-4615-2632-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation